NOX1 and pulmonary fibrosis: This narrative review critically discusses the role of NOX1/4‐mediated ROS production in liver, kidney and lung fibrosis, the pre‐clinical evidence in support of setanaxib as a therapeutic agent in the pre‐clinical setting, and the potential clinical translatability of such pre‐clinical evidence.